2026-06-27T22:48:33Zhttps://docta.ucm.es/rest/oai/request
oai:docta.ucm.es:20.500.14352/44342024-07-04T13:43:58Zcom_20.500.14352_14col_20.500.14352_15
Docta Complutense author Martínez De La Casa Fernández-Borrella, José María author Sáenz Francés, Federico author Morales Fernández, Laura author Perucho González, Lucía author Méndez Hernández, Carmen Dora author Fernández Vidal, Ana M. author García Sáenz, Sofía author Sánchez Jean, Rubén author García Feijoo, Julián 2023-06-16T14:15:59Z 2023-06-16T14:15:59Z 2021-08-02 Martínez De La Casa Fernández-Borrella, J. M., Sáenz Francés, F., Morales Fernández, L. et al. «Clinical Outcomes of Combined Preserflo Microshunt Implantation and Cataract Surgery in Open-Angle Glaucoma Patients». Scientific Reports, vol. 11, n.o 1, agosto de 2021, p. 15600. DOI.org (Crossref), https://doi.org/10.1038/s41598-021-95217-x. 2045-2322 10.1038/s41598-021-95217-x https://hdl.handle.net/20.500.14352/4434 https://doi.org/10.1038/s41598-021-95217-x http://www.nature.com/srep/index.html To assess the effectiveness and safety of the Preserflo Microshunt (PMS) implantation combined with cataract surgery in open-angle glaucoma (OAG) patients. Retrospective, open-label study conducted on insufficiently controlled OAG patients, who underwent a PMS implant procedure with mitomycin-C 0.2%, either alone or in combination with cataract surgery, and were followed for at least 12 months. Success was defined as an intraocular pressure (IOP) ≤ 18 mmHg and a reduction of at least 20% without (complete) or with (qualified) hypotensive medication. Fifty-eight eyes were included in the study, 35 eyes underwent PMS alone and 23 underwent PMS + Phaco. In the overall study sample, mean IOP was significantly lowered from 21.5 ± 3.3 mmHg at baseline to 14.6 ± 3.5 mmHg at month 12 (p < 0.0001). The IOP was significantly reduced in both groups; p < 0.0001 each, respectively. Ocular hypotensive medication was significantly reduced (p < 0.0001) in both groups. No significant differences were observed in IOP lowering or medication reduction between groups. At month 12, 62.1% eyes were considered as complete success and 82.8% eyes as qualified success. The most common adverse events were device close-to-endothelium, conjunctival fibrosis, and wound leakage. PMS, either alone or in combination with phacoemulsification, may be considered as a valuable option for treating OAG patients. eng Atribución 3.0 España Clinical outcomes of combined Preserflo Microshunt implantation and cataract surgery in open-angle glaucoma patients journal article URL https://docta.ucm.es/bitstreams/a1993ba4-9fd0-4918-989c-af1d6b1b1868/download File MD5 c2479c814c8f8c2b659b102c56ff59e7 1074956 application/pdf s41598-021-95217-x.pdf URL https://docta.ucm.es/bitstreams/2ee0c7a7-bada-4e0b-8804-ea31d92cab83/download File MD5 f4938122d7c47797cc8a880c900fd7ad 36640 text/plain s41598-021-95217-x.pdf.txt